



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

## Complete if Known

Application Number	10/594,162
Filing Date	September 26, 2006
First Name Inventor	Bartsch
Group Art Unit	
Examiner Name	
Attorney Docket Number	22393

Sheet	1	of	3
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No.'	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>o</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	B1	WO 98/58915			Boehringer Mannheim GMBH	12-30-1998	
	B2	WO 00/40962			KOSAK	07-13-2000	
	B3	WO 01/25217			F. Hoffmann-La Roche AG	04-12-2001	
	B4	WO 02/089824			F. Hoffmann-La Roche AG	11-14-2002	
	B5	WO 97/23465			Boehringer Mannheim GMBH	07-03-1997	
	B6	WO 00/37109			Euphar Group SRL	06-29-2000	
	B7	WO 2005/097058			Hoffmann-La Roche AG	10-20-2005	
	B8	EP 1 018 340			Tecnimede-Sociedade Technico-Medicinal	07-12-2000	
Examiner Signature		Date Considered /Leigh Maier/				01/02/2009	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Acronym is to place a check mark here if English language Translation or abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/



Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Application Number	10/594,162
		Filing Date	September 26, 2006
		First Name Inventor	Bartsch
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	22393
Sheet	2	Of	3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>a</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	Egeblad, M., and Werb, Z., Nat. Rev. Cancer 2 (2002) 161-174;	
	C2	Overall, C.M., and Lopez-Otin, C., Nat. Rev. Cancer 2 (2002) 657-672	
	C3	Holmbeck, K., et al., Cell 99 (1999) 81-92	
	C4	Vu, T.H., et al., Cell 93 (1998) 411-422	
	C5	Shapiro, S.D., Curr. Opin. Cell Biol. 10 (1998) 602-608	
	C6	Lund, L.R., et al., EMBO J. 18 (1999) 4645-4656	
	C7	Carmeliet, P., et al., Nat. Genet. 17 (1997) 439-444	
	C8	Chang, C., and Werb, D., Trends Cell Biol. 11 (2001) S37-43	
	C9	Manes, S., et al., J. Biol. Chem. 274 (1999) 6935-6945	
	C10	Bergers, G., et al., Nat. Cell Biol. 2 (2000) 737-744	
	C11	Dong, Z., et al., Cell 88 (1997) 801-810	
	C12	Janowska-Wieczorek, A., et al., Blood 93 (1999) 3379-3390	
	C13	Carstansen, D., et al., Transfusion 42 (2002) 588-596	
	C14	Grams, F., et al., Biol. Chem. 382 (2001) 1277-1285	
	C15	Ansel, H., et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed., (1995), pp. 196 and 1456-1457	
	C16	Fabbri, L.M., and Hurd, S.S., Eur. Respir. J. 22 (2003) 1-2	
	C17	Higuchi, T., and Connors, K.A., Advances in Analytical Chemistry and Instrumentation 4 (1965) 117-212	
	C18	Yu, Z., and Westerlund, D., Chromatographia 44 (1997) 589-594	
	C19	Hubert, Ph., et al., S. T. P. Pharma Pratiques 9 (1999) 160-180	
	C20	Souverain, S., et al., Journal of Chromatography B 801 (2004) 141-156)	
	C21	Chiap, P., et al., Journal of Chromatography B 817 (2005), 109-117	
	C22	Hubert, P., et al., Analytica Chimica Acta 391 (1999) 135-148;	
	C23	Hubert, Ph., et al., J. Pharm. Biomed. Anal. 36 (2004) 579-586	
	C24	Hamelmann, E., et al., Am. J Respir. Crit. Care Med. 156 (1997) 766-775	
	C25	Cataldo, D.D., et al, Am. J. Pathol. 161 (2002) 491-498	
	C26	Aki, et al. Jour of Pharm Sci, V. 90 (2001) 1186-1197	
	C27	Csabai, Int Jour of Pharm 91 (1993) 15-22	
	C28	Foley, Bio & Med Chem Ltr (2001) 969-972	
	C29	Kotzumi, 94 (1974) 1515	
	C30	Lopata, Jour of Phar Sci, 74 (1985) 211-213	



C31	Mura, Eur Jour of Pharm (2005) 99-106	
C32	Piel, Jour of Pharm Sci, 86 (1997) 475-480	
C33	Szejtli, Cyclodextrin Tech (1988) 186-307	
C34	Iwaoku, Chem Pharm Bull (1982) 1416-1421	
C35	Loukas, Int Jour of Pharm 226 (2001) 207-211	
C36	Suzuki, Chem Pharm Bull (1993) 1444-1447	
C37	Lein, Oncogene (2002) 2089-2096	
C38	Mura, Int Jour Pharm 260 (2003) 293-302	
Examiner Signature	/Leigh Maier/	DATE CONSIDERED
		01/02/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation or abstract is attached.

257509

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/